
A controversial paper on the safety and immunogenicity of an Iran-made COVID-19 vaccine is being investigated by the U.S.-based publisher Wiley, Retraction Watch has learned.
Iran reportedly has already administered 3 million doses of the vaccine, dubbed Noora, which the country licensed for emergency use last year.
The paper describes the vaccine’s first test in humans, marking the only time results from the clinical development of the homegrown shot have been reported in international journals.
“Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial” was published in 2022 in the Journal of Medical Virology, an achievement highlighted in Iranian news media. One report said the study showed a dose of 80 micrograms of the vaccine was “safe” and provided “adequate immunity in adults.”
Continue reading Publisher looking into COVID vaccine paper with ‘serious flaws’